Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER plus metastatic breast cancer. Rosen, E., Sharma, M., Berz, D., Caswell-Jin, J., Spira, A. I., Fulgar, G. A., Densel, M., Rana, N., Sperry, S., Warner, D., Meric-Bernstam, F., ASCO Authors' Grp LIPPINCOTT WILLIAMS & WILKINS. 2023

View details for Web of Science ID 001053772000190